Cost-consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada by Virender Bhan, Fraser Clift, Moogeh Baharnoori, Kimberly Thomas, Barkha P Patel, Francois Blanchette, Nicholas Adlard, Umakanth Vudumula, Kapil Gudala, Nikkita Dutta, Daniel Grima, Soukaina Mouallif, Fatine Farhane

Connect to this object online.